Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy

By Brian Buntz | March 11, 2022

Novartis (NYSE:NVS) has inked a deal with the biopharma Carisma Therapeutics focused on the production of human epidermal growth factor receptor 2 (HER2)-targeted chimeric antigen receptor macrophages (CAR-M) to potentially treat solid tumors.

Carisma is headquartered in Philadelphia.

As part of the deal, Carisma will shift manufacturing to a Novartis cell therapy site in Morris Plains, New Jersey.

Novartis anticipates clinical manufacturing to begin in 2023.

Get the full story from our sister site, Drug Discovery & Development.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.